Compare PXED & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | NNNN |
|---|---|---|
| Founded | 1976 | 2021 |
| Country | United States | Germany |
| Employees | 3400 | 27 |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | PXED | NNNN |
|---|---|---|
| Price | $33.11 | $14.53 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $44.29 | N/A |
| AVG Volume (30 Days) | ★ 82.1K | 36.2K |
| Earning Date | 04-07-2026 | 04-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | ★ $11.20 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $10.50 |
| 52 Week High | $38.19 | $55.65 |
| Indicator | PXED | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 31.90 |
| Support Level | $28.40 | $14.66 |
| Resistance Level | $33.05 | $30.21 |
| Average True Range (ATR) | 1.34 | 2.37 |
| MACD | 0.07 | -0.19 |
| Stochastic Oscillator | 91.44 | 8.90 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).